CALB2 and Miyoshi myopathy: We demonstrated that serum calretinin concentration was higher in patients with a worse treatment outcome and shorter PFS and OS from the beginning of chemotherapy, even after adjusting for clinical factors, suggesting that it could serve as an independent predictive biomarker in MM patients treated with cisplatin-based chemotherapy.